Primary biliary cholangitis: pathogenesis and therapeutic opportunities
The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Abstract
Primary biliary cholangitis is a chronic, seropositive and female-predominant inflammatory and cholestatic liver disease, which has a variable rate of progression towards biliary cirrhosis. Substantial progress has been made in patient risk stratification with the goal of personalized care, including early adoption of next-generation therapy with licensed use of obeticholic acid or off-label fibrate derivatives for those with insufficient benefit from ursodeoxycholic acid, the current first-line drug. The disease biology spans genetic risk, epigenetic changes, dysregulated mucosal immunity and altered biliary epithelial cell function, all of which interact and arise in the context of ill-defined environmental triggers. A current focus of research on nuclear receptor pathway modulation that specifically and potently improves biliary excretion, reduces inflammation and attenuates fibrosis is redefining therapy. Patients are benefiting from pharmacological agonists of farnesoid X receptor and peroxisome proliferator-activated receptors. Immunotherapy remains a challenge, with a lack of target definition, pleiotropic immune pathways and an interplay between hepatic immune responses and cholestasis, wherein bile acid-induced inflammation and fibrosis are dominant clinically. The management of patient symptoms, particularly pruritus, is a notable goal reflected in the development of rational therapy with apical sodium-dependent bile acid transporter inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“diversity of the intestinal microbiome is decreased in treatment-naive primary biliary cholangitis patients 34,35 with a unique intestinal microbiota composed of elevated levels of Enterobacteriaceae, Pseudomonas, Veillonella, and Clostridium, along with reduced levels of Oscillospira and Suterella.33”
From Primary biliary cholangitis. (2024) · cites this paper as [33]
Citations
Cites
Items 201–236 of 236
Triantis, V., Saeland, E., Bijl, N., Oude‐Elferink, R. P., & Jansen, P. L. M. (2010) · Hepatology · doi:10.1002/hep.23708 · Cited by 55
Nakagawa, R., Muroyama, R., Saeki, C., Goto, K., Kaise, Y., Koike, K., Nakano, M., Matsubara, Y., Takano, K., Ito, S., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.002 · Cited by 52
Animal Models of Primary Biliary Cirrhosis
Wang, J., Yang, G.-X., Tsuneyama, K., Gershwin, M., Ridgway, W., & Leung, P. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1383728 · Cited by 49
CD8 T Cells Mediate Direct Biliary Ductule Damage in Nonobese Diabetic Autoimmune Biliary Disease
Yang, G.-X., Wu, Y., Tsukamoto, H., Leung, P. S., Lian, Z.-X., Rainbow, D. B., Hunter, K. M., Morris, G. A., Lyons, P. A., Peterson, L. B., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001597 · Cited by 49
Genetic variations in interleukin-12 related genes in immune-mediated diseases
van Wanrooij, R. L. J., Zwiers, A., Kraal, G., & Bouma, G. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.06.002 · Cited by 46
Haruta, I., Kikuchi, K., Hashimoto, E., Nakamura, M., Miyakawa, H., Hirota, K., Shibata, N., Kato, H., Arimura, Y., Kato, Y., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.40 · Cited by 44
Towards common denominators in primary biliary cirrhosis: The role of IL-12
Lleo, A., Gershwin, M. E., Mantovani, A., & Invernizzi, P. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.040 · Cited by 42
Interaction between Fenofibrate and Warfarin
Ascah, K. J., Rock, G. A., & Wells, P. S. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17310 · Cited by 42
[DNA typing of HLA class II genes].
Kimura, A., & Sasazuki, T. (1990) · PubMed · Cited by 40
Dysregulation of Circulating Tfr/Tfh Ratio in Primary biliary cholangitis
Zheng, J., Wang, T., Zhang, L., & Cui, L. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12616 · Cited by 40
Atif, M., Warner, S., & Oo, Y. H. (2018) · Hepatology International · doi:10.1007/s12072-018-9882-x · Cited by 40
Vitamin D modulates biliary fibrosis in ABCB4-deficient mice
Hochrath, K., Stokes, C. S., Geisel, J., Pollheimer, M. J., Fickert, P., Dooley, S., & Lammert, F. (2014) · Hepatology International · doi:10.1007/s12072-014-9548-2 · Cited by 36
Human CYP7A1 deficiency: progress and enigmas
Beigneux, A. P., Hofmann, A. F., & Young, S. G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216076 · Cited by 36
Lehr, T., Staab, A., Tillmann, C., Trommeshauser, D., Schaefer, H.-G., & Kloft, C. (2009) · Clinical Pharmacokinetics · doi:10.2165/11313370-000000000-00000 · Cited by 35
Ma, H.-D., Ma, W.-T., Liu, Q.-Z., Zhao, Z.-B., Liu, M.-Z.-Y., Tsuneyama, K., Gao, J.-M., Ridgway, W. M., Ansari, A. A., Gershwin, M. E., et al. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.12.012 · Cited by 35
Bile Acids and Deregulated Cholangiocyte Autophagy in Primary Biliary Cholangitis
Sasaki, M., & Nakanuma, Y. (2017) · Digestive Diseases · doi:10.1159/000450913 · Cited by 35
Human CYP7A1 deficiency: progress and enigmas
Beigneux, A. P., Hofmann, A. F., & Young, S. G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16076 · Cited by 34
MECHANISM OF HEPATOPROTECTIVE ACTION OF BILE SALTS IN LIVER DISEASE
Stiehl, A., Benz, C., & Sauer, P. (1999) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70050-9 · Cited by 33
Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes
Lleò, A., Shimoda, S., Ishibashi, H., & Gershwin, M. E. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0303-8 · Cited by 32
Murine models of autoimmune cholangitis
Ueno, Y., Ambrosini, Y. M., Moritoki, Y., Ridgway, W. M., & Gershwin, M. E. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32833755aa · Cited by 32
Yasunami, M., Nakamura, H., Tokunaga, K., Kawashima, M., Nishida, N., Hitomi, Y., & Nakamura, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-11148-6 · Cited by 32
Chang, J., Go, S., Verhoeven, A. J., Beuers, U. H., & Elferink, R. P. J. O. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.022 · Cited by 32
Takigawa, T., Miyazaki, H., Kinoshita, M., Kawarabayashi, N., Nishiyama, K., Hatsuse, K., Ono, S., Saitoh, D., Seki, S., & Yamamoto, J. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00205.2012 · Cited by 31
High-definition PBC: biology, models and therapeutic advances
Webb, G. J., & Hirschfield, G. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.201 · Cited by 31
Self-citationPersistent reduction of mucosal‐associated invariant T cells in primary biliary cholangitis
Setsu, T., Yamagiwa, S., Tominaga, K., Kimura, N., Honda, H., Kamimura, H., Tsuchiya, A., Takamura, M., & Terai, S. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14076 · Cited by 31
Zhang, Y., Chen, K., Dai, W., Xia, Y., Wang, F., Shen, M., Cheng, P., Wang, C., Yang, J., Zhu, R., et al. (2014) · Hepatology Research · doi:10.1111/hepr.12373 · Cited by 30
The Immunogenetics of Autoimmune Cholestasis
Trivedi, P. J., & Hirschfield, G. M. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.08.002 · Cited by 29
Self-citationApotopes and innate immune system: Novel players in the primary biliary cirrhosis scenario
Lleò, A., & Invernizzi, P. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.01.005 · Cited by 28
Steroidal or non-steroidal FXR agonists – Is that the question?
Verbeke, L., Nevens, F., & Laleman, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.013 · Cited by 25
Mucosal IgA defect in primary biliary cirrhosis
Floreani, A., Baragiotta, A. M., Pizzuti, D., Martines, D., Cecchetto, A., & Chiarelli, S. M. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05521.x · Cited by 24
Treiner, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00027 · Cited by 22
d'Aldebert, E., Mve, M.-J. B. B., Mergey, M., Wendum, D., Coilly, A., Fouassier, L., Corpechot, C., Poupon, R. Y., Housset, C., & Chignard, N. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9644-0_13 · Cited by 17
Follicles, germinal centers, and immune mechanisms in primary biliary cirrhosis
Webb, G. J., & Hirschfield, G. M. (2014) · Hepatology · doi:10.1002/hep.27552 · Cited by 15
Self-citationHirschfield, G. M., Kupčinskas, L., Ott, P., Beuers, U. H., Bergquist, A. M., Färkkilä, M. A., Manns, M. P., Parés, A. R., Spengler, U., Greinwald, R., et al. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30293-9 · Cited by 12
Self-citationPrimary biliary cholangitis, DNA, and beyond: The Relative contribution of genes
Gulamhusein, A. F., & Lazaridis, K. N. (2018) · Hepatology · doi:10.1002/hep.29783 · Cited by 9
Self-citationBezafibrate in Primary Biliary Cholangitis.
Corpechot, C., Chazouillères, O., & Rousseau, A. (2018) · PubMed · doi:10.1056/nejmc1809061 · Cited by 8
Research works printed but not linked: 1
- Cordell, H. J. et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat. Commun. 6, 8019 (2015). · DOI · Paper page
Cited by
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Recent clinical studies further indicate improvement of histological features, including fibrosis in patients with PBC after long-terms OCA treatment [305].”
BackgroundContribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders
Chopyk, D. M., & Grakoui, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.077 · Cited by 490
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Self-citationRecent advances in clinical practice: Epidemiology of autoimmune liver diseases
Trivedi, P. J., & Hirschfield, G. M. (2021) · Gut · doi:10.1136/gutjnl-2020-322362 · Cited by 244
Self-citation
Metadata
- Authors
- Gulamhusein, A. F., & Hirschfield, G. M.
- Affiliations
- University Health Network (CA)
- Corresponding author
- Hirschfield, Gideon M.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2019-12-09
- Volume
- 17
- Issue
- 2
- Pages
- 93-110
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W2993976670
- Cited by
- 308
- References
- 236
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 62 · 2023: 57 · 2022: 53 · 2021: 33 · 2020: 19
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary biliary cirrhosis, pathogenesis, obeticholic acid, ursodeoxycholic acid, farnesoid X receptor, peroxisome proliferator-activated receptors, liver fibrosis, biliary cirrhosis, risk stratification, pruritus, nuclear receptor agonists, immunotherapy, cholestasis, cholangiocytes, epigenetic modifications
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Chenodeoxycholic Acid, Cholagogues and Choleretics, Environmental Exposure, Humans, Immunity, Innate, Liver Cirrhosis, Liver Cirrhosis, Biliary, Ursodeoxycholic Acid, Autoimmunity, Receptors, Cytoplasmic and Nuclear, Disease Progression, Chloride-Bicarbonate Antiporters, Symporters, Organic Anion Transporters, Sodium-Dependent, MicroRNAs, Epigenesis, Genetic, Peroxisome Proliferator-Activated Receptors, Dihydrolipoyllysine-Residue Acetyltransferase, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.